
A potential game-changer in blood and marrow transplantation
By N. G. Boeck / For Fred Hutch News Service
Researchers at Fred Hutch Cancer Center are studying whether a lower dose of post-transplant cyclophosphamide could help prevent graft-versus-host disease while reducing treatment-related side effects. This promising work may help improve recovery, immune function, and quality of life for future blood and marrow transplant patients.













